Clinicopathological characteristics associated with the prognosis of recurrent gonadotroph tumors.

Endocrine-related cancer Pub Date : 2025-05-13 Print Date: 2025-06-01 DOI:10.1530/ERC-24-0186
Chrysi Kaparounaki, Alexandre Vasiljevic, Emmanuel Jouanneau, Camille Sergeant, Gérald Raverot, Mirela-Diana Ilie
{"title":"Clinicopathological characteristics associated with the prognosis of recurrent gonadotroph tumors.","authors":"Chrysi Kaparounaki, Alexandre Vasiljevic, Emmanuel Jouanneau, Camille Sergeant, Gérald Raverot, Mirela-Diana Ilie","doi":"10.1530/ERC-24-0186","DOIUrl":null,"url":null,"abstract":"<p><p>Although gonadotroph tumor regrowth is frequent after pituitary surgery, the systematic use of adjuvant radiotherapy is limited by its long-term complications. In this context, it is important to predict which tumors are most likely to regrow after surgery, and especially, which tumors are most likely to regrow rapidly. Clinicopathological characteristics associated with the prognosis of radiotherapy-naïve, recurrent pituitary tumors are currently unknown. In this longitudinal, observational, retrospective, monocentric cohort study, we analyzed the clinicopathological characteristics associated with the prognosis of recurrent, radiotherapy-naïve gonadotroph tumors, specifically with the progression-free survival after a second pituitary surgery. We found that the Ki67 index of radiotherapy-naïve, recurrent gonadotroph tumors was the only parameter statistically associated with the progression-free survival after a second pituitary surgery, P = 0.02. Specifically, radiotherapy-naïve gonadotroph tumors with a positive Ki67 index had shorter progression-free survival after the second surgery (median 31 months) compared to radiotherapy-naïve gonadotroph tumors with a negative Ki67 index (median 75 months). Thus, our study pinpoints that the Ki67 index could be used to guide the management strategy for recurrent gonadotroph tumors that are still radiotherapy-naïve by the time of the second pituitary surgery.</p>","PeriodicalId":93989,"journal":{"name":"Endocrine-related cancer","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Endocrine-related cancer","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1530/ERC-24-0186","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/6/1 0:00:00","PubModel":"Print","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Although gonadotroph tumor regrowth is frequent after pituitary surgery, the systematic use of adjuvant radiotherapy is limited by its long-term complications. In this context, it is important to predict which tumors are most likely to regrow after surgery, and especially, which tumors are most likely to regrow rapidly. Clinicopathological characteristics associated with the prognosis of radiotherapy-naïve, recurrent pituitary tumors are currently unknown. In this longitudinal, observational, retrospective, monocentric cohort study, we analyzed the clinicopathological characteristics associated with the prognosis of recurrent, radiotherapy-naïve gonadotroph tumors, specifically with the progression-free survival after a second pituitary surgery. We found that the Ki67 index of radiotherapy-naïve, recurrent gonadotroph tumors was the only parameter statistically associated with the progression-free survival after a second pituitary surgery, P = 0.02. Specifically, radiotherapy-naïve gonadotroph tumors with a positive Ki67 index had shorter progression-free survival after the second surgery (median 31 months) compared to radiotherapy-naïve gonadotroph tumors with a negative Ki67 index (median 75 months). Thus, our study pinpoints that the Ki67 index could be used to guide the management strategy for recurrent gonadotroph tumors that are still radiotherapy-naïve by the time of the second pituitary surgery.

复发性性腺功能瘤的临床病理特征与预后的关系。
虽然垂体手术后促性腺瘤再生是常见的,但辅助放疗的系统使用受到其长期并发症的限制。在这种情况下,预测哪些肿瘤最有可能在手术后再生,特别是哪些肿瘤最有可能快速再生是很重要的。与radiotherapy-naïve复发性垂体肿瘤的预后相关的临床病理特征目前尚不清楚。在这项纵向、观察性、回顾性、单中心队列研究中,我们分析了与复发性radiotherapy-naïve促性腺功能肿瘤预后相关的临床病理特征,特别是与第二次垂体手术后的无进展生存期相关的临床病理特征。我们发现,复发性促性腺功能肿瘤radiotherapy-naïve的Ki67指数是第二次垂体手术后无进展生存的唯一统计学参数,p = 0.02。具体来说,与Ki67指数阴性的radiotherapy-naïve促性腺激素肿瘤(中位75个月)相比,radiotherapy-naïve Ki67指数阳性的促性腺激素肿瘤在第二次手术后的无进展生存期(中位31个月)更短。因此,我们的研究指出,Ki67指数可用于指导到第二次垂体手术时仍为radiotherapy-naïve的复发性性腺激素肿瘤的治疗策略。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信